Sihuan Pharmaceutical Holdings Group Ltd. (SHPHF)

OTCMKTS · Delayed Price · Currency is USD
0.1000
-0.0218 (-17.90%)
May 7, 2025, 4:00 PM EDT
73.91%
Market Cap 838.26M
Revenue (ttm) 260.46M
Net Income (ttm) -29.68M
Shares Out n/a
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend 0.00 (2.70%)
Ex-Dividend Date Sep 27, 2024
Volume 200
Average Volume 2,520
Open 0.1218
Previous Close 0.1218
Day's Range 0.1000 - 0.1218
52-Week Range 0.0492 - 0.1218
Beta 0.58
RSI 51.22
Earnings Date n/a

About SHPHF

Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical and medical aesthetic products in the People’s Republic of China. The company operates through three segments: Medical Aesthetic Products, Innovative Medicine and Other Medicine, and Generic Medicine. It offers filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care, and others, as well as non- or minimally invasive medical aesthetics compreh... [Read more]

Sector Healthcare
Founded 2001
Employees 2,667
Stock Exchange OTCMKTS
Ticker Symbol SHPHF
Full Company Profile

Financial Performance

In 2024, SHPHF's revenue was 1.90 billion, an increase of 2.18% compared to the previous year's 1.86 billion. Losses were -216.66 million, 301.1% more than in 2023.

Financial numbers in CNY Financial Statements

News

Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, Its Innovative Drug Anaprozole Sodium Enteric-coated Tablets Obtains Drug Registration Approval From NMPA

HONG KONG , June 27, 2023 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd together with its subsidiaries, is pleased to announce that Xuanzhu Biopharmaceutical Co., Ltd. ("Xuanzhu Biopharm"),...

2 years ago - PRNewsWire